GO:0071346 cellular response to type II interferon: Signaling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0071346 describes the entire set of cellular changes triggered by interferon-gamma (IFN-gamma), the only type II interferon.
• IFN-gamma signaling is a central node in cancer immunotherapy, where it can drive both adaptive anti-tumor immunity and innate resistance programs.
• The pathway is highly cell-type specific: neutrophils, macrophages, dendritic cells, epithelial cells, and tumor cells each mount distinct type II interferon responses [1,2,5].
• Tissue-specific IFN-gamma abundance shapes regulatory T cell and dendritic cell crosstalk in lung cancer and other tumors.
• Pathogens such as Chlamydia trachomatis actively modulate JAK-STAT components to attenuate the epithelial type II interferon response.
• CRISPR knockout, knock-in, and overexpression models are essential to dissect causal genes within this pathway and to validate immunotherapy targets [3,8].
Description
The cellular response to type II interferon (GO:0071346) is the collection of molecular and cellular changes that occur when a cell encounters interferon-gamma (IFN-gamma), the sole member of the type II interferon family. This response is fundamental to host defense, immune regulation, and cancer immunosurveillance, and it is initiated when IFN-gamma binds its receptor and activates JAK-STAT signaling to reprogram gene expression. Because IFN-gamma acts on nearly every cell type, the downstream response is highly context-dependent and can be either protective or pathogenic. In cancer, type II interferon signaling is a double-edged sword: it supports cytotoxic T cell priming and antigen presentation, yet chronic IFN-gamma exposure can drive adaptive resistance to immune checkpoint blockade. In infectious disease, pathogens have evolved mechanisms to dampen the type II interferon response, as shown for Chlamydia trachomatis in epithelial cells. Understanding GO:0071346 therefore requires integrating cell-type-specific signaling, transcriptional outputs, and functional outcomes across immunology, oncology, and microbiology [1,2,5]. Researchers studying this term need robust experimental systems, including CRISPR-engineered cell models, to determine which genes causally shape the response and how they can be therapeutically targeted [3,8].
cellular response to type II interferon At A Glance
| GO ID | GO:0071346 |
|---|---|
| GO term | cellular response to type II interferon |
| Ontology | biological_process |
| Synonym | cellular response to gamma-interferon; cellular response to immune interferon; cellular response to interferon-gamma; cellular response to type II IFN |
| Major function | Mediates cellular changes triggered by interferon-gamma, including gene expression, secretion, movement, and enzyme production |
| Stimulus | Interferon-gamma (IFN-gamma), the only known type II interferon |
| Key signaling route | JAK-STAT pathway activation leading to transcriptional reprogramming [3,5] |
| Cell types involved | Neutrophils, macrophages, dendritic cells, epithelial cells, T cells, and tumor cells [1,2,5,6] |
| Disease relevance | Cancer immunotherapy response and resistance, infectious disease, and autoimmune inflammation [3,5,8] |
What Is GO:0071346?
GO:0071346, cellular response to type II interferon, is defined as any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an interferon-gamma stimulus. Interferon gamma is the only member of the type II interferon family identified so far, so this term specifically covers cellular responses to IFN-gamma and not to type I or type III interferons. The response includes rapid signaling events, transcriptional reprogramming, and downstream functional changes such as altered antigen presentation, cytokine secretion, and cell growth control.
Why Is cellular response to type II interferon Important in Cell Biology?
GO:0071346 is important because IFN-gamma is a master regulator of immune surveillance, and the cellular response to it determines whether a tissue mounts effective immunity or becomes resistant to therapy. In cancer, type II interferon signaling in neutrophils, myeloid cells, and tumor cells can control immunotherapy outcomes, and manipulating this response may improve checkpoint blockade efficacy [1,8]. In infectious disease, the ability of pathogens to attenuate the type II interferon response directly impacts host defense. Because the pathway is so central, it is a high-priority target for functional genomics and CRISPR screening [3,8].
• Controls anti-tumor immunity and shapes response to immune checkpoint blockade.
• Regulates neutrophil-dependent immunotherapy efficacy in cancer.
• Drives myeloid cell-mediated resistance to immunotherapy in renal cell carcinoma.
• Shapes tissue-specific regulatory T cell and dendritic cell crosstalk in lung cancer.
• Is targeted by pathogens such as Chlamydia trachomatis to attenuate epithelial responses.
• Modulates macrophage polarization and inflammatory programs in vitro.
• Influences B cell depletion strategies in autoimmune mucosal pemphigus vulgaris.
• Is affected by hormones such as testosterone in neutrophils during hepatic amebiasis.
• Provides a mechanistic basis for understanding interferon-driven autoimmunity and inflammation.
• Offers a rich source of targets for CRISPR knockout, knock-in, and overexpression studies [3,8].
What Happens During cellular response to type II interferon?
IFN-gamma recognition and receptor activation
In simple terms: The cell detects interferon-gamma through its receptor, like a lock recognizing a key.
The cellular response to type II interferon begins when IFN-gamma binds to the IFN-gamma receptor complex on the cell surface, triggering receptor dimerization and activation of associated JAK kinases. This event is the committed step that distinguishes type II interferon signaling from type I responses and initiates downstream phosphorylation of STAT1. In epithelial cells, this step can be modulated by pathogens that alter JAK-STAT component expression.
JAK-STAT signal transduction and transcriptional reprogramming
In simple terms: Signals travel from the receptor to the nucleus, where they switch many genes on or off.
Activated JAK kinases phosphorylate STAT1, which translocates to the nucleus and drives expression of interferon-stimulated genes. This transcriptional program changes antigen presentation, cytokine secretion, and cell growth, and its intensity and duration determine whether the response is protective or tolerogenic [3,6]. Chlamydia trachomatis can attenuate this step by modulating JAK-STAT signaling components in epithelial cells.
Cell-type-specific effector programs
In simple terms: Different cells respond to the same signal in different ways.
Neutrophils, macrophages, dendritic cells, and epithelial cells each execute distinct type II interferon effector programs [1,2,5]. In neutrophils, type II interferon controls immunotherapy efficacy and can be influenced by hormones such as testosterone during hepatic amebiasis [1,7]. Macrophages polarize toward inflammatory states in response to IFN-gamma in vitro, while dendritic cells integrate IFN-gamma signals to prime cytotoxic T cells in lung cancer.
Integration with adaptive immunity and immunotherapy
In simple terms: The response helps coordinate the whole immune system, which matters for cancer treatment.
Type II interferon signaling in the tumor microenvironment coordinates adaptive and innate immune responses to immune checkpoint blockade. Tissue-specific IFN-gamma abundance drives regulatory T cells to restrain dendritic cell-mediated priming of cytotoxic T cells in lung cancer. In advanced renal cell carcinoma, myeloid cells mediate interferon-driven resistance to immunotherapy, highlighting the clinical importance of this pathway.
Pathogen evasion and modulation
In simple terms: Some microbes try to turn down the interferon alarm.
Pathogens have evolved strategies to attenuate the type II interferon response. Chlamydia trachomatis modulates the expression of JAK-STAT signaling components to dampen the epithelial response, reducing IFN-gamma-driven gene expression. This evasion mechanism illustrates how the cellular response to type II interferon is a battleground between host and pathogen.
Key Genes Involved in GO:0071346 cellular response to type II interferon
The following genes and proteins are central to the cellular response to type II interferon and are frequently studied using CRISPR models.
| Gene | Major Role | Research Relevance |
|---|---|---|
| IFNG | Encodes interferon-gamma, the type II interferon ligand | Central stimulus for GO:0071346; target for knockout and overexpression studies |
| IFNGR1 | Type II interferon receptor subunit 1 | Mediates IFN-gamma binding and receptor activation |
| IFNGR2 | Type II interferon receptor subunit 2 | Required for signaling complex assembly and JAK activation |
| JAK1 | Janus kinase 1 | Phosphorylates STAT1 downstream of IFN-gamma receptor [3,5] |
| JAK2 | Janus kinase 2 | Partners with JAK1 to transduce type II interferon signals [3,5] |
| STAT1 | Signal transducer and activator of transcription 1 | Key transcription factor driving interferon-stimulated genes |
| IRF1 | Interferon regulatory factor 1 | Transcription factor downstream of STAT1 that shapes IFN-gamma responses |
| SOCS1 | Suppressor of cytokine signaling 1 | Negative regulator of JAK-STAT signaling |
| PIAS1 | Protein inhibitor of activated STAT1 | Modulates STAT1 activity and interferon responses |
| CXCL9 | Chemokine induced by IFN-gamma | Recruits T cells and marks active type II interferon signaling |
| CXCL10 | Chemokine induced by IFN-gamma | Recruits cytotoxic T cells and is a readout of GO:0071346 |
| MHC class I genes | Antigen presentation machinery | Upregulated by IFN-gamma to enhance immune recognition |
| MHC class II genes | Antigen presentation to CD4 T cells | Induced by IFN-gamma in macrophages and dendritic cells [2,6] |
| NOS2 | Inducible nitric oxide synthase | Effector molecule in IFN-gamma-activated macrophages |
| IL12B | Interleukin 12 subunit beta | Links type II interferon to Th1 immune responses |
| TAP1 | Transporter associated with antigen processing | Required for peptide loading onto MHC class I after IFN-gamma stimulation |
| B2M | Beta-2-microglobulin | Essential for MHC class I surface expression and IFN-gamma responses |
| PD-L1 (CD274) | Immune checkpoint ligand | Regulated by IFN-gamma and linked to immunotherapy resistance [3,8] |
How Is cellular response to type II interferon Regulated?
The cellular response to type II interferon is tightly regulated at multiple levels. JAK-STAT signaling is controlled by negative feedback regulators such as SOCS1 and PIAS1, which limit the duration and intensity of STAT1 activation. In cancer, chronic IFN-gamma exposure can reprogram cells toward adaptive resistance, and myeloid cells can mediate interferon-driven resistance to immunotherapy in renal cell carcinoma. Tissue-specific IFN-gamma abundance further modulates the response by shaping regulatory T cell and dendritic cell interactions in lung cancer. Pathogens such as Chlamydia trachomatis can attenuate the response by altering JAK-STAT component expression. Hormonal factors, including testosterone, can also affect type I and type II interferon responses in neutrophils during hepatic amebiasis.
cellular response to type II interferon and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| IFNG | Cancer immunotherapy response and resistance | IFNG knockout tumor cells or overexpression models [1,3] |
| STAT1 | Interferon-driven resistance in renal cell carcinoma | STAT1 knockout or point-mutation cell lines [3,8] |
| JAK1 | Pathogen evasion and immunotherapy resistance | JAK1 knockout epithelial cells |
| CXCL10 | T cell recruitment in lung cancer | CXCL10 reporter knock-in in tumor cells |
| PD-L1 (CD274) | Immune checkpoint regulation | PD-L1 knockout or tagged knock-in for imaging [3,8] |
Cancer immunotherapy response and resistance
Type II interferon signaling has opposing functions in cancer: it supports adaptive anti-tumor immunity but can also drive innate resistance programs that limit checkpoint blockade efficacy. Neutrophil regulation of immunotherapy is controlled by type II interferon, making this pathway a target for combination strategies. In advanced renal cell carcinoma, myeloid cells mediate interferon-driven resistance, suggesting that blocking specific type II interferon outputs could improve outcomes. Tissue-specific IFN-gamma abundance in lung cancer drives regulatory T cells to restrain dendritic cell-mediated priming of cytotoxic T cells, revealing another layer of immune regulation.
Infectious disease and pathogen evasion
The cellular response to type II interferon is critical for controlling intracellular pathogens, and some microbes actively attenuate it. Chlamydia trachomatis modulates JAK-STAT signaling components to reduce the epithelial type II interferon response, which may contribute to persistent infection. In hepatic amebiasis, testosterone affects type I and type II interferon responses of neutrophils, highlighting hormonal modulation of this pathway during infection.
Autoimmune and inflammatory conditions
IFN-gamma-driven responses contribute to autoimmune tissue damage. In mucosal pemphigus vulgaris, antigen-specific B cell depletion is being explored as a precision therapy, and the type II interferon axis may influence B cell and T cell interactions in this disease. Macrophage polarization assays in vitro are used to study how IFN-gamma shapes inflammatory macrophage states relevant to autoimmunity.
From cellular response to type II interferon-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does a candidate gene causally drive IFN-gamma-induced gene expression? | CRISPR knockout in relevant cell line followed by RNA-seq |
| Does a specific phosphorylation site in STAT1 control the response? | Point-mutation knock-in of STAT1 phospho-mutant |
| How does a gene of interest localize after IFN-gamma stimulation? | Tagged knock-in with fluorescent or epitope tag |
| Can overexpression of a negative regulator dampen the type II interferon response? | Overexpression cell model with inducible promoter [3,8] |
| Which genes mediate neutrophil-dependent immunotherapy response? | CRISPR library screening in neutrophils or myeloid cells [1,8] |
| How do pathogens modulate JAK-STAT components? | Knockout epithelial cells infected with Chlamydia trachomatis |
How to Study the cellular response to type II interferon Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Transcriptional changes after IFN-gamma stimulation | Identify interferon-stimulated genes and regulators |
| Phosphoproteomics | Phosphorylation of JAK-STAT components | Study signaling dynamics and pathogen modulation |
| Flow cytometry | Surface markers such as MHC class I and PD-L1 | Functional readout of type II interferon response |
| CRISPR knockout screening | Genes required for IFN-gamma response | Discover immunotherapy targets [3,8] |
| Macrophage polarization assay | Cytokine secretion and surface markers | Study IFN-gamma effects on macrophages in vitro |
| Imaging of tagged knock-in | Subcellular localization of STAT1 or IRF1 | Visualize signaling dynamics |
| Neutrophil functional assays | Immunotherapy efficacy in co-culture | Study type II interferon control of neutrophils |
| Pathogen infection models | JAK-STAT component expression | Investigate Chlamydia trachomatis evasion |
Transcriptomic profiling of the type II interferon response
RNA-seq after IFN-gamma stimulation is a standard method to measure the transcriptional output of GO:0071346. This approach identifies interferon-stimulated genes and can be combined with CRISPR knockout to determine which regulators are required for specific gene expression programs. In cancer models, RNA-seq has revealed opposing adaptive and innate immune programs downstream of interferon signaling.
Proteomic and phosphoproteomic analysis
Mass spectrometry-based proteomics can quantify JAK-STAT phosphorylation and downstream protein changes after IFN-gamma treatment. This is particularly useful for studying how pathogens such as Chlamydia trachomatis alter JAK-STAT component expression. Phosphoproteomics can also identify feedback regulators such as SOCS1 that shape the response.
Flow cytometry and imaging of immune cell responses
Flow cytometry is used to measure surface markers such as MHC class I and PD-L1 after IFN-gamma stimulation, providing a functional readout of the type II interferon response. Imaging of tagged knock-in proteins can reveal subcellular localization and dynamics of STAT1 or IRF1. Macrophage polarization assays use flow cytometry and cytokine profiling to assess IFN-gamma effects in vitro.
CRISPR screening and functional genomics
Genome-wide CRISPR screens are powerful for identifying genes that regulate the cellular response to type II interferon. Such screens have been used to uncover mechanisms of immunotherapy resistance and to map pathways controlling IFN-gamma-driven gene expression [3,8]. In neutrophils and myeloid cells, targeted screens can reveal cell-type-specific regulators of immunotherapy efficacy [1,8].
How CRISPR Can Be Used to Study GO:0071346 cellular response to type II interferon
Knockout
CRISPR knockout is used to delete candidate genes such as STAT1, JAK1, or IFNGR1 to test their requirement for the cellular response to type II interferon [3,5]. Knockout of negative regulators like SOCS1 can enhance the response, while knockout of positive regulators abolishes IFN-gamma-induced gene expression. In cancer models, knockout screens have identified genes that mediate immunotherapy resistance downstream of type II interferon.
Point Mutation
Point-mutation knock-in allows precise modification of phosphorylation sites or DNA-binding residues in STAT1 or IRF1 to dissect their functional domains. This approach can reveal whether specific post-translational modifications are required for the type II interferon response. Point mutations in JAK1 or JAK2 can also model clinical resistance mutations.
Knock-in
Tagged knock-in of genes such as STAT1, IRF1, or CXCL10 enables live-cell imaging and chromatin immunoprecipitation to study their dynamics after IFN-gamma stimulation [3,6]. Knock-in of reporter cassettes can provide sensitive readouts of pathway activity in high-throughput screens.
Overexpression
Overexpression of IFN-gamma, STAT1, or negative regulators like SOCS1 can amplify or dampen the type II interferon response, respectively [3,8]. Inducible overexpression systems allow temporal control of pathway activation, which is useful for studying adaptive resistance in cancer cells.
How EDITGENE Supports cellular response to type II interferon Research
Researchers studying cellular response to type II interferon-related genes often need to determine whether a candidate gene is causally involved in the pathway or merely correlated with it. EDITGENE provides CRISPR-engineered cell models and screening services to establish causality and accelerate therapeutic target validation.
Contact EDITGENE today to design your custom CRISPR model for cellular response to type II interferon research.
Frequently Asked Questions About cellular response to type II interferon
What is GO:0071346 cellular response to type II interferon?
GO:0071346 is a Gene Ontology biological process term describing all cellular changes triggered by interferon-gamma, the only type II interferon, including gene expression, secretion, and movement.
What genes are involved in cellular response to type II interferon?
Key genes include IFNG, IFNGR1, IFNGR2, JAK1, JAK2, STAT1, IRF1, SOCS1, CXCL9, CXCL10, and MHC class I and II genes [1,3,5].
How does interferon-gamma signal inside the cell?
IFN-gamma binds its receptor, activates JAK kinases, and phosphorylates STAT1, which moves to the nucleus and turns on interferon-stimulated genes.
Why is type II interferon important in cancer immunotherapy?
Type II interferon signaling supports anti-tumor immunity but can also drive resistance to immune checkpoint blockade, making it a key target for combination therapies [3,8].
How do pathogens evade the type II interferon response?
Chlamydia trachomatis modulates JAK-STAT signaling components to attenuate the epithelial type II interferon response, reducing IFN-gamma-driven gene expression.
What cell types respond to interferon-gamma?
Neutrophils, macrophages, dendritic cells, epithelial cells, T cells, and tumor cells all mount cell-type-specific responses to IFN-gamma [1,2,5,6].
What is the difference between type I and type II interferon responses?
Type I interferons include IFN-alpha and IFN-beta, while type II interferon is only IFN-gamma; GO:0071346 specifically covers responses to IFN-gamma.
How can CRISPR be used to study cellular response to type II interferon?
CRISPR knockout, knock-in, point mutation, and overexpression models can test whether specific genes are required for IFN-gamma-induced gene expression and immune functions [3,8].
What diseases are linked to type II interferon signaling?
Type II interferon signaling is linked to cancer immunotherapy response and resistance, infectious diseases such as Chlamydia infection, and autoimmune conditions [3,4,5,8].
What methods are used to measure the type II interferon response?
Common methods include RNA-seq, phosphoproteomics, flow cytometry, imaging of tagged proteins, and CRISPR screens [2,3,5].
Conclusion
GO:0071346 cellular response to type II interferon is a central biological process that integrates immune signaling, transcriptional reprogramming, and cell-type-specific effector functions [1,3]. Its dual role in promoting anti-tumor immunity and driving immunotherapy resistance makes it a high-value target for functional genomics and therapeutic development [3,8]. CRISPR-engineered cell models and screening approaches are essential to dissect the causal genes within this pathway and to translate these insights into clinical benefit [3,8].
References
- 1. Pei S et al.. 2026. Neutrophil regulation of immunotherapy for cancer is controlled by type II interferon.. Immunity 59(7):1982-1998.e6 PMID: 42296966
- 2. Huang X et al.. 2018. Polarizing Macrophages In Vitro.. Methods Mol Biol 1784:119-126 PMID: 29761394
- 3. Benci JL et al.. 2019. Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade.. Cell 178(4):933-948.e14 PMID: 31398344
- 4. Lee J et al.. 2020. Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris.. J Clin Invest 130(12):6317-6324 PMID: 32817591
- 5. Fontanilla FL et al.. 2024. Chlamydia trachomatis modulates the expression of JAK-STAT signaling components to attenuate the type II interferon response of epithelial cells.. mBio 15(10):e0183424 PMID: 39194253
- 6. Zagorulya M et al.. 2023. Tissue-specific abundance of interferon-gamma drives regulatory T cells to restrain DC1-mediated priming of cytotoxic T cells against lung cancer.. Immunity 56(2):386-405.e10 PMID: 36736322
- 7. Er-Lukowiak M et al.. 2023. Testosterone affects type I/type II interferon response of neutrophils during hepatic amebiasis.. Front Immunol 14:1279245 PMID: 38179044
- 8. Bi K et al.. 2025. Myeloid cells mediate interferon-driven resistance to immunotherapy in advanced renal cell carcinoma.. Immunity 58(11):2814-2829.e9 PMID: 41175876
